Abu Dhabi welcomes the opening of the Burjeel Cancer Institute (BCI) in Mohammed bin Zayed City, a state-of-the-art facility dedicated to providing advanced cancer treatments. The institute spans four floors and includes private chemotherapy suites, specialty clinics, a dedicated breast cancer unit, and other patient-focused amenities.
Launched by Burjeel Holdings, according to a Khaleej Times report, the BCI integrates various advanced treatments, such as chemotherapy, immunotherapy, surgical oncology, stereotactic radiosurgery (SRS), and stereotactic body radiotherapy (SBRT). Additionally, the institute offers cutting-edge options like targeted therapy, precision medicine, and AI-driven cancer diagnosis and management.
Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and Coexistence, inaugurated the institute. “Caring for cancer patients in the UAE is a top priority,” Sheikh Nahyan emphasized, highlighting the UAE’s commitment to comprehensive and innovative cancer care. “The facilities hosted by the UAE, such as the BCI, reflect our dedication to providing comprehensive and innovative care for cancer patients. Their unique vision includes not only treatment but also prevention, early detection, and patient education.”
BCI serves as the hub of Burjeel’s extensive cancer care network, which includes facilities in Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai. This network supports over 5,000 oncology patients annually, performs more than 10,000 screenings, and conducts over 10,000 radiotherapy sessions with the expertise of more than 50 specialists.
Dr. Shamsheer Vayalil, founder and chairman of Burjeel Holdings, highlighted the transformative impact of the new institute on cancer treatment. “We are committed to ensuring that patients receive the best possible care, supported by advanced technology and research,” he stated.
Leading Emirati oncologist Prof. Humaid Al Shamsi, head of the institute, underscored the provision of free consultations. “We are making a statement. We are trying to provide better care and quality experience for patients,” he said, noting the integration of advanced diagnostic tools and cutting-edge treatments.
The institute features advanced diagnostic capabilities through OncoHelix-CoLab, enabling specialized tests using technologies like next-generation sequencing (NGS), droplet digital PCR, and multi-color flow cytometry. BCI is also equipped to conduct clinical trials and translational research.
Additionally, the institute plans to establish a medical education program to enhance oncology education, support research, and develop residency and fellowship programs in collaboration with local and global institutions. Community engagement initiatives will include awareness campaigns, educational seminars, and cancer screening programs.
